Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Versartis Reports Fourth Quarter 2016 Financial Results
MENLO PARK, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced financial
View HTML
Toggle Summary Versartis Promotes Joshua T. Brumm to Chief Operating Officer and Paul Westberg to Chief Business Officer
MENLO PARK, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), announced the
View HTML
Toggle Summary Versartis' Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO 2017
  36-month data in pediatric GHD, showing consistent safety and efficacy profile through 3 years of treatment Baseline characteristics of Phase 3 VELOCITY study population comparable to Phase 2 Additional results from the VITAL trial in adult GHD MENLO PARK, Calif., Jan.
View HTML
Toggle Summary Versartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society
Increasing somavaratan dose to the 3.5mg/kg twice-monthly now used in Phase 3 safely improved IGF-I SDS and height velocity from year 1 to year 2
View HTML
Toggle Summary Versartis Reports Third Quarter 2016 Financial Results
MENLO PARK, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis to Present at Two Investor Conferences in November
MENLO PARK, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis Announces Pricing of Follow-On Offering
MENLO PARK, Calif., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis Announces Proposed Offering of Common Stock
MENLO PARK, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2
MENLO PARK, Calif., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML
Toggle Summary Versartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting
MENLO PARK, Calif., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused biopharmaceutical company that is developing somavaratan (VRS-317), a novel, long-acting form of recombinant human growth hormone (rhGH) for growth hormone deficiency (GHD), today announced
View HTML